TRINETRA › Sectors › Healthcare
Healthcare Global Enterprises Limited (HCG) — share price, P/E and fundamentals
Healthcare Global Enterprises Limited (NSE: HCG) closed at ₹585.00 on 30 Oct 2026, -20.3% over one year, against a 52-week range of ₹513.30 – ₹804.65.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹695 cr and net profit of ₹14 cr, a 2.0% net margin; revenue grew 13.4% and profit grew 114.4% year on year.
On four consecutive filed quarters its trailing P/E is 383.4; since 26 May 2025 its own P/E has ranged from 165.7 to 707.6 (median 352.9), and today's reading is higher than 51% of those 354 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 4.1%, ROCE 8.7%, debt-to-equity 0.68, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 6% of 63 sector peers; PBT margin higher than 6% of 63 sector peers; ROE higher than 13% of 63 sector peers.
Key figures
| Last close | ₹585.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -16.6% / +2.7% / -20.3% |
| 52-week low – high | ₹513.30 – ₹804.65 |
| Market capitalisation | ₹8,734 cr |
| Trailing P/E | 383.4 |
| Price / book | 6.56 |
| EV / EBITDA | 19.6 |
| Earnings yield | 0.3% |
| TTM EPS | ₹1.53 |
| TTM net profit | ₹23 cr |
| Quarter revenue | ₹695 cr |
| Quarter net profit | ₹14 cr |
| Net margin | 2.0% |
| Revenue growth (YoY) | +13.4% |
| Profit growth (YoY) | +114.4% |
| Return on equity | 4.1% |
| ROCE | 8.7% |
| Debt / equity | 0.68 |
| Current ratio | 1.09 |
| Free cash flow | ₹55 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹6.8 cr |
Against Healthcare peers
| Metric | HCG | Peer median | Percentile |
|---|---|---|---|
| Net margin | 1.98 | 12.89 | 6 |
| PBT margin | 3.47 | 17.68 | 6 |
| ROE | 4.14 | 13.87 | 13 |
| ROCE | 8.70 | 17.26 | 16 |
| Debt / equity | 0.68 | 0.11 | 94 |
| Cash conversion | 15.24 | 1.25 | 100 |
| Trailing P/E | 383.41 | 43.07 | 100 |
| P/B | 6.56 | 5.88 | 59 |
Questions
What is the P/E ratio of Healthcare Global Enterprises Limited?
Healthcare Global Enterprises Limited's trailing P/E is 383.4, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 26 May 2025 its P/E has ranged 165.7–707.6.
What were Healthcare Global Enterprises Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Healthcare Global Enterprises Limited reported revenue of ₹695 cr and net profit of ₹14 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Healthcare Global Enterprises Limited's ROE?
Return on equity is 4.1% based on the balance sheet dated 31 Mar 2026.
Does Healthcare Global Enterprises Limited have debt?
Debt-to-equity is 0.68 on the balance sheet dated 31 Mar 2026.
What is HCG's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, HCG traded between ₹513.30 and ₹804.65.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.